Literature DB >> 30017880

Combination of Asiatic Acid and Naringenin Modulates NK Cell Anti-cancer Immunity by Rebalancing Smad3/Smad7 Signaling.

Guang-Yu Lian1, Qing-Ming Wang1, Patrick Ming-Kuen Tang2, Shuang Zhou1, Xiao-Ru Huang1, Hui-Yao Lan3.   

Abstract

Transforming growth factor β1 (TGF-β1) plays a promoting role in tumor growth via a mechanism associated with hyperactive Smad3 and suppressed Smad7 signaling in the tumor microenvironment. We report that retrieving the balance between Smad3 and Smad7 signaling with asiatic acid (AA, a Smad7 inducer) and naringenin (NG, a Smad3 inhibitor) effectively inhibited tumor progression in mouse models of invasive melanoma (B16F10) and lung carcinoma (LLC) by promoting natural killer (NK) cell development and cytotoxicity against cancer. Mechanistically, we found that Smad3 physically bound Id2 and IRF2 to suppress NK cell production and NK cell-mediated cytotoxicity against cancer. Treatment with AA and NG greatly inhibited Smad3 translation and phosphorylation while it restored Smad7 expression, and, therefore, it largely promoted NK cell differentiation, maturation, and cytotoxicity against cancer via Id2/IRF2-associated mechanisms. In contrast, silencing Id2 or IRF2 blunted the protective effects of AA and NG on NK cell-dependent anti-cancer activities. Thus, treatment with AA and NG produced an additive effect on inactivating TGF-β1/Smad3 signaling, and, therefore, it suppressed melanoma and lung carcinoma growth by promoting NK cell immunity against cancer via a mechanism associated with Id2 and IRF2.
Copyright © 2018 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  NK cell immunity; anti-cancer immunotherapy; rebalancing Smad3/Smad7 signaling

Mesh:

Substances:

Year:  2018        PMID: 30017880      PMCID: PMC6127879          DOI: 10.1016/j.ymthe.2018.06.016

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  59 in total

Review 1.  TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression.

Authors:  Li Yang; Yanli Pang; Harold L Moses
Journal:  Trends Immunol       Date:  2010-06-01       Impact factor: 16.687

2.  TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance.

Authors:  Dori A Thomas; Joan Massagué
Journal:  Cancer Cell       Date:  2005-11       Impact factor: 31.743

3.  Asiatic acid induces apoptosis in SK-MEL-2 human melanoma cells.

Authors:  Byung Chul Park; Kefa O Bosire; Eung-Seok Lee; Yong Soo Lee; Jung-Ae Kim
Journal:  Cancer Lett       Date:  2005-01-31       Impact factor: 8.679

Review 4.  TGF-beta signalling from cell membrane to nucleus through SMAD proteins.

Authors:  C H Heldin; K Miyazono; P ten Dijke
Journal:  Nature       Date:  1997-12-04       Impact factor: 49.962

Review 5.  TGFbeta in Cancer.

Authors:  Joan Massagué
Journal:  Cell       Date:  2008-07-25       Impact factor: 41.582

6.  Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands.

Authors:  Marco Wendel; Ioanna E Galani; Elisabeth Suri-Payer; Adelheid Cerwenka
Journal:  Cancer Res       Date:  2008-10-15       Impact factor: 12.701

7.  Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation.

Authors:  François Ghiringhelli; Pierre E Puig; Stephan Roux; Arnaud Parcellier; Elise Schmitt; Eric Solary; Guido Kroemer; François Martin; Bruno Chauffert; Laurence Zitvogel
Journal:  J Exp Med       Date:  2005-09-26       Impact factor: 14.307

8.  Smad3 promotes cancer progression by inhibiting E4BP4-mediated NK cell development.

Authors:  Patrick Ming-Kuen Tang; Shuang Zhou; Xiao-Ming Meng; Qing-Ming Wang; Chun-Jie Li; Guang-Yu Lian; Xiao-Ru Huang; Yong-Jiang Tang; Xin-Yuan Guan; Bryan Ping-Yen Yan; Ka-Fai To; Hui-Yao Lan
Journal:  Nat Commun       Date:  2017-03-06       Impact factor: 14.919

9.  TGF-β is responsible for NK cell immaturity during ontogeny and increased susceptibility to infection during mouse infancy.

Authors:  Jeffrey P Marcoe; James R Lim; Keri L Schaubert; Nassima Fodil-Cornu; Marsel Matka; Alexandra L McCubbrey; Alexander R Farr; Silvia M Vidal; Yasmina Laouar
Journal:  Nat Immunol       Date:  2012-08-05       Impact factor: 25.606

10.  Naringenin decreases invasiveness and metastasis by inhibiting TGF-β-induced epithelial to mesenchymal transition in pancreatic cancer cells.

Authors:  Changjie Lou; Fayun Zhang; Ming Yang; Juan Zhao; Wenfeng Zeng; Xiaocui Fang; Yanqiao Zhang; Chunling Zhang; Wei Liang
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240

View more
  11 in total

Review 1.  Recent Advances Regarding the Molecular Mechanisms of Triterpenic Acids: A Review (Part I).

Authors:  Marius Mioc; Andreea Milan; Daniel Malița; Alexandra Mioc; Alexandra Prodea; Roxana Racoviceanu; Roxana Ghiulai; Andreea Cristea; Florina Căruntu; Codruța Șoica
Journal:  Int J Mol Sci       Date:  2022-07-13       Impact factor: 6.208

2.  Naringenin and cryptotanshinone shift the immune response towards Th1 and modulate T regulatory cells via JAK2/STAT3 pathway in breast cancer.

Authors:  Shokoofe Noori; Mitra Nourbakhsh; Hossein Imani; Niloofar Deravi; Niloufar Salehi; Zohreh Abdolvahabi
Journal:  BMC Complement Med Ther       Date:  2022-05-23

3.  Combination antiretroviral therapy (cART)-induced hippocampal disorders: Highlights on therapeutic potential of Naringenin and Quercetin.

Authors:  Edidiong N Akang
Journal:  IBRO Rep       Date:  2019-04-24

4.  Asiatic Acid, Extracted from Centella asiatica and Induces Apoptosis Pathway through the Phosphorylation p38 Mitogen-Activated Protein Kinase in Cisplatin-Resistant Nasopharyngeal Carcinoma Cells.

Authors:  Yen-Tze Liu; Yi-Ching Chuang; Yu-Sheng Lo; Chia-Chieh Lin; Yi-Ting Hsi; Ming-Ju Hsieh; Mu-Kuan Chen
Journal:  Biomolecules       Date:  2020-01-25

Review 5.  Nrf2 Signaling Pathway in Chemoprotection and Doxorubicin Resistance: Potential Application in Drug Discovery.

Authors:  Sepideh Mirzaei; Ali Zarrabi; Farid Hashemi; Amirhossein Zabolian; Hossein Saleki; Negar Azami; Soodeh Hamzehlou; Mahdi Vasheghani Farahani; Kiavash Hushmandi; Milad Ashrafizadeh; Haroon Khan; Alan Prem Kumar
Journal:  Antioxidants (Basel)       Date:  2021-02-26

6.  AANG: A natural compound formula for overcoming multidrug resistance via synergistic rebalancing the TGF-β/Smad signalling in hepatocellular carcinoma.

Authors:  Jeff Yat-Fai Chung; Max Kam-Kwan Chan; Philip Chiu-Tsun Tang; Alex Siu-Wing Chan; Justin Shing-Yin Chung; Xiao-Ming Meng; Ka-Fai To; Hui-Yao Lan; Kam-Tong Leung; Patrick Ming-Kuen Tang
Journal:  J Cell Mol Med       Date:  2021-09-12       Impact factor: 5.310

Review 7.  Targeting transforming growth factor-β signalling for cancer prevention and intervention: Recent advances in developing small molecules of natural origin.

Authors:  Devesh Tewari; Anu Priya; Anusha Bishayee; Anupam Bishayee
Journal:  Clin Transl Med       Date:  2022-04

Review 8.  Natural products and their derivatives: Promising modulators of tumor immunotherapy.

Authors:  Li-Juan Deng; Ming Qi; Nan Li; Yu-He Lei; Dong-Mei Zhang; Jia-Xu Chen
Journal:  J Leukoc Biol       Date:  2020-07-17       Impact factor: 4.962

9.  Prolactin Acts on Myeloid Progenitors to Modulate SMAD7 Expression and Enhance Hematopoietic Stem Cell Differentiation into the NK Cell Lineage.

Authors:  Dejene M Tufa; Tyler Shank; Ashley M Yingst; George Devon Trahan; Seonhui Shim; Jessica Lake; Renee Woods; Kenneth Jones; Michael R Verneris
Journal:  Sci Rep       Date:  2020-04-14       Impact factor: 4.379

10.  Naringenin potentiates anti-tumor immunity against oral cancer by inducing lymph node CD169-positive macrophage activation and cytotoxic T cell infiltration.

Authors:  Sho Kawaguchi; Kenta Kawahara; Yukio Fujiwara; Koji Ohnishi; Cheng Pan; Hiromu Yano; Akiyuki Hirosue; Masashi Nagata; Masatoshi Hirayama; Junki Sakata; Hikaru Nakashima; Hidetaka Arita; Keisuke Yamana; Shunsuke Gohara; Yuka Nagao; Manabu Maeshiro; Asuka Iwamoto; Mayumi Hirayama; Ryoji Yoshida; Yoshihiro Komohara; Hideki Nakayama
Journal:  Cancer Immunol Immunother       Date:  2022-01-19       Impact factor: 6.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.